CINECA IRIS Institutional Research Information System

FERRARI, SILVIA MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.984
AS - Asia 7.760
EU - Europa 6.216
SA - Sud America 1.490
Continente sconosciuto - Info sul continente non disponibili 909
AF - Africa 260
OC - Oceania 21
Totale 35.640
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.456
IT - Italia 2.496
SG - Singapore 2.386
CN - Cina 2.095
HK - Hong Kong 1.348
BR - Brasile 1.239
SE - Svezia 857
VN - Vietnam 801
BG - Bulgaria 523
DE - Germania 473
FI - Finlandia 425
CA - Canada 385
FR - Francia 318
GB - Regno Unito 308
RU - Federazione Russa 301
TR - Turchia 289
IN - India 167
UA - Ucraina 114
IQ - Iraq 95
JP - Giappone 94
BD - Bangladesh 92
NL - Olanda 90
AR - Argentina 84
MX - Messico 61
CI - Costa d'Avorio 60
PL - Polonia 53
KR - Corea 48
ID - Indonesia 43
AT - Austria 41
ES - Italia 41
ZA - Sudafrica 40
EC - Ecuador 38
CO - Colombia 35
PK - Pakistan 32
SA - Arabia Saudita 32
MA - Marocco 31
SN - Senegal 30
VE - Venezuela 30
CH - Svizzera 29
BE - Belgio 26
PH - Filippine 25
NG - Nigeria 24
UZ - Uzbekistan 24
PY - Paraguay 22
CZ - Repubblica Ceca 20
AU - Australia 18
IE - Irlanda 18
JM - Giamaica 18
JO - Giordania 18
MY - Malesia 16
TN - Tunisia 16
IR - Iran 15
NP - Nepal 15
RO - Romania 15
TH - Thailandia 15
AE - Emirati Arabi Uniti 14
KE - Kenya 14
LT - Lituania 12
PE - Perù 12
UY - Uruguay 12
GT - Guatemala 11
CL - Cile 10
DZ - Algeria 10
EG - Egitto 10
OM - Oman 10
AL - Albania 9
DO - Repubblica Dominicana 9
IL - Israele 9
KZ - Kazakistan 9
TW - Taiwan 9
HN - Honduras 8
LB - Libano 8
GR - Grecia 7
TT - Trinidad e Tobago 7
BH - Bahrain 6
BJ - Benin 6
BY - Bielorussia 6
HU - Ungheria 6
PS - Palestinian Territory 6
RS - Serbia 6
CR - Costa Rica 5
GE - Georgia 5
NI - Nicaragua 5
AM - Armenia 4
AZ - Azerbaigian 4
BN - Brunei Darussalam 4
BO - Bolivia 4
BS - Bahamas 4
DK - Danimarca 4
ET - Etiopia 4
EU - Europa 4
GY - Guiana 4
KG - Kirghizistan 4
PA - Panama 4
PT - Portogallo 4
QA - Qatar 4
BB - Barbados 3
HR - Croazia 3
KW - Kuwait 3
MD - Moldavia 3
Totale 34.690
Salva come PNG Salva come JPEG
Città #
Ashburn 1.995
Fairfield 1.867
Woodbridge 1.526
Singapore 1.350
Hong Kong 1.329
Houston 1.063
Dallas 1.045
San Jose 939
Santa Clara 897
Ann Arbor 840
Seattle 818
Chandler 796
Serra 790
Cambridge 685
Wilmington 664
Shanghai 536
Sofia 522
Milan 505
Beijing 446
Council Bluffs 424
New York 377
Boardman 266
Princeton 257
Pisa 255
Los Angeles 246
Helsinki 241
Ottawa 237
Lawrence 205
Medford 196
Lauterbourg 182
Ho Chi Minh City 169
Nanjing 146
Dong Ket 139
Izmir 134
Des Moines 131
Munich 118
Jacksonville 115
São Paulo 111
Hanoi 102
Buffalo 100
London 100
Istanbul 99
Columbus 97
Florence 97
Redondo Beach 96
Frankfurt am Main 89
San Diego 87
Rome 83
Tokyo 83
The Dalles 78
Hefei 77
Dearborn 73
Abidjan 60
Boulder 52
Chicago 48
Seoul 47
Paris 45
Phoenix 41
Nanchang 40
Rio de Janeiro 40
Redwood City 39
Kunming 37
Ogden 37
Warsaw 37
Da Nang 36
Toronto 36
Falls Church 35
Fuzhou 35
Turku 35
Washington 35
Baghdad 33
Bremen 33
Shenyang 33
Brooklyn 32
Hebei 32
Changsha 31
Dakar 30
Norwalk 29
Nuremberg 29
Montreal 28
San Francisco 27
Belo Horizonte 26
Amsterdam 25
Brussels 25
Dhaka 25
Jiaxing 24
Pune 24
Johannesburg 23
Rho 23
Denver 22
Guangzhou 22
Haiphong 22
Orem 22
Sulaymaniyah 22
Tashkent 22
Tianjin 22
Vienna 22
Chennai 21
Lagos 20
Brasília 19
Totale 25.326
Salva come PNG Salva come JPEG
Nome #
Autoimmune thyroid disorders 336
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 256
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 253
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy 253
Hepatitis C Virus Infection: Evidence for an Association With Type 2 Diabetes: Response to Skowronski et al. 247
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 242
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 235
Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. 231
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 231
Molecular testing in the diagnosis of differentiated thyroid carcinomas 229
Aggressive thyroid cancer: targeted therapy with sorafenib 228
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 228
Sorafenib in the treatment of thyroid cancer 228
Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature 225
Sunitinib in the treatment of thyroid cancer 225
Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia 222
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors 218
Sorafenib and Thyroid Cancer 216
Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts 213
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 211
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases 211
The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients 206
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study 203
TSH Normalization in Bariatric Surgery Patients After the Switch from l-Thyroxine in Tablet to an Oral Liquid Formulation 200
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 198
Selective use of vandetanib in the treatment of thyroid cancer 198
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy 198
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors 196
CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer 195
New insight in endocrine-related adverse events associated to immune checkpoint blockade 195
Increased CXCL9 Serum Levels in Hepatitis C-Related Mixed Cryoglobulinemia, with Autoimmune Thyroiditis, Associated with High Levels of CXCL10 194
Cabozantinib in Thyroid Cancer 194
Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied 193
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 193
Novel therapies for thyroid autoimmune diseases: An update 192
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone 190
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses 190
Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection 189
Thyroid disorders induced by checkpoint inhibitors 189
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 188
Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ 188
Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide 186
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition 186
DICER1 Syndrome: A Multicenter Surgical Experience and Systematic Review 185
CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes 184
Myo-inositol in autoimmune thyroiditis, and hypothyroidism 184
Cytokines and HCV-Related Disorders. 180
Cytokines and HCV-related autoimmune disorders 180
Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine 180
Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study 179
Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy 179
Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. 178
Novel treatments for anaplastic thyroid carcinoma 178
RET TKI: Potential Role in Thyroid Cancers 177
High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C 173
New targeted molecular therapies for dedifferentiated thyroid cancer. 169
Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells 168
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series 168
The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine 168
3,5-diiodo-l-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. 167
New targeted therapies for anaplastic thyroid cancer. 167
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy 167
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests 167
Thyroid involvement in hepatitis C - Associated mixed cryoglobulinemia 166
Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy 165
Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells 165
Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C? 165
Endocrine Manifestations of HCV-Positive Cryoglobulinemia 164
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy 164
Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up 164
Thyroid uptake of 67Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis. 163
Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up 163
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update 162
Novel treatment options for anaplastic thyroid cancer 162
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration 162
Immune and inflammatory cells in thyroid cancer microenvironment 162
Chemokines in thyroid autoimmunity 161
Current and future immunotherapies for thyroid cancer 160
High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-γ. 160
Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. 159
Nutraceuticals in thyroidology: A review of in vitro, and in vivo animal studies 159
Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis 158
Both 3,5-diiodo-L-thyronine (T2) and T3 modulate glucose-induced insulin secretion 158
The emerging extrahepatic manifestations oh hepatitis C virus infection in chronic hepatitis and mixed cryoglobulinemia. 157
Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer 155
Thyroid Autoimmunity and SARS-CoV-2 Infection 155
Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. 155
Recent advances in precision medicine for the treatment of anaplastic thyroid cancer 155
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. 154
Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. 154
Tyrosine Kinase Inhibitors; Therapies for Thyroid Cancer 154
CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide 154
Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies 154
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin 153
Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. 153
Hepatitis C virus infection - Evidence for an association with type 2 diabetes 153
Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro 151
Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects. 151
High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. 151
Novel Therapies for Thyroid Autoimmune Diseases 151
Totale 18.549
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.915
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.915
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.453 0 116 112 158 412 329 75 163 133 86 166 703
2022/20232.421 361 293 160 194 271 340 46 166 353 11 189 37
2023/20242.112 183 233 257 183 315 385 118 73 35 43 69 218
2024/20257.032 158 267 112 444 702 911 574 395 604 868 724 1.273
2025/20268.837 656 1.001 1.160 734 728 797 1.354 417 501 880 258 351
2026/2027906 311 595 0 0 0 0 0 0 0 0 0 0
Totale 35.640